UNSPSC 51314370: Diphenhydramine/pseudoephedrine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE501. This VA Drug Class (RE501) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT.

UNSPSC 51314370 Diphenhydramine/pseudoephedrine is a Commodity code that captures state and local government purchase of specific pharmaceutical products and OTC medications, though recent solicitation activity tagged under this code shows minimal alignment with the nominal product scope. The three most recent opportunities span naloxone and drug-deactivation systems procurement, direct-to-manufacturer pharmacy benefit programs, and generic multi-source pharmaceutical supply agreements — none of which center on diphenhydramine or pseudoephedrine compounds specifically. State and local issuing bodies soliciting under or related to this code include county health departments, state health and human services agencies, and multistate cooperative purchasing alliances. Seminole County, Florida, the Texas Health and Human Services Commission, and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) represent the visible buyers in recent activity.

Recent opportunities span Florida, Texas, and Minnesota. Seminole County's IFB60459723LAS, posted June 30, 2026, with response due July 26, 2023, seeks 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding with quarterly deliveries to Sanford, Florida. The Texas HHS Commission issued RFI HHS0017013 on April 3, 2026, as exploratory market intelligence on direct-to-manufacturer prescription programs for the Therapeutic Pharmacy Initiative, indicating future formal procurement but no current contract award. MMCAP's RFP S1070000015802, posted January 20, 2026, with proposals due March 26, 2026, establishes multi-award contracts for generic pharmaceuticals and OTC products across participating state and local facilities including Minnesota and Oregon, with distribution through AmerisourceBergen (Cencora), Cardinal Health, and Morris & Dickson, and pricing weighted 75 percent on competitiveness. The code shows little recent activity directly aligned to diphenhydramine/pseudoephedrine procurement; opportunities appear misclassified or reflect broader pharmaceutical purchasing categories that state and local procurement systems apply to ancillary medication lines.